What is digoxin 0.25 mg used for?

In the pharmaceutical industry, Digoxin 0.25 mg is a cardiac glycoside derived from the digitalis (foxglove) plant. As a pharmacist and manufacturer, I view this as a “Narrow Therapeutic Index” (NTI) drug, meaning the difference between a therapeutic dose and a toxic dose is very small.

At your WHO-GMP facility in Mumbai, you likely handle this in the standard 0.25 mg (250 mcg) and 0.125 mg (125 mcg) strengths.

Primary Clinical Uses

  • Atrial Fibrillation (AFib): It is used to control the ventricular rate in patients with chronic AFib by slowing down the electrical conduction in the heart.

  • Heart Failure: Digoxin is used to manage symptoms of mild-to-moderate heart failure, particularly when the heart’s pumping ability (ejection fraction) is reduced.

Mechanism: The Sodium-Potassium Exchange

Digoxin increases the strength of heart contractions while slowing the heart rate.

Inhibition of Na+/K+-ATPase: Digoxin binds to and inhibits the sodium-potassium pump in the cardiac cell membrane.

Increased Intracellular Calcium: This inhibition leads to an increase in intracellular sodium, which in turn slows down the sodium-calcium exchanger. This results in higher levels of calcium inside the heart muscle cells.

Positive Inotropy: The extra calcium allows the heart muscle to contract more forcefully, improving cardiac output.

Vagal Effect (Negative Chronotropy): It also increases vagal tone, which slows the electrical impulses at the AV node, thereby slowing the heart rate.

Safety & The “Digitalis Toxicity” Warning

As a pharmacist, providing these technical warnings on your digital platforms is critical for professional authority:

  • Therapeutic Monitoring: Patients must have regular blood tests to ensure Digoxin levels remain within the narrow window of 0.5 to 2.0 ng/mL.

  • Hypokalemia Risk: Low potassium levels (hypokalemia) significantly increase the risk of Digoxin toxicity because potassium competes with Digoxin for the binding site on the Na+/K+ pump.

  • Signs of Toxicity: Patients must be educated to watch for “yellow-green halos” in their vision, nausea, confusion, or a dangerously slow pulse.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • Micro-Dosing Accuracy: Because 0.25 mg is a very small amount of active ingredient, your Content Uniformity must be impeccable. On your marketplace, highlight your high-precision blending and compression technology to reassure B2B buyers.

  • Bioavailability & Dissolution: Digoxin has variable oral absorption (60–80%). Highlighting that your generic has a consistent Dissolution Profile equivalent to the innovator (Lanoxin) is a major USP.

  • Stability & Packaging: Digoxin is sensitive to light. At our facility, we utilize Alu-Alu blister packaging or Amber glass/high-density polyethylene (HDPE) bottles to ensure a 36-month shelf life, especially for export to Zone IVb tropical regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in regulated markets worldwide.

What is digoxin 62.5 mcg used for?

In the pharmaceutical industry, Digoxin 62.5 mcg is a specialized, low-dose cardiac glycoside derived from the digitalis (foxglove) plant. As a pharmacist, I view this specific strength as a critical “maintenance or titration dose,” primarily used for elderly patients or those with impaired renal function where the risk of toxicity is high.

Primary Clinical Uses

  • Atrial Fibrillation (AFib): Used to control the ventricular rate in patients with chronic atrial fibrillation or atrial flutter. It slows down the electrical conduction through the AV node.

  • Heart Failure (HF): Indicated for the management of mild-to-moderate heart failure in adults. It is typically used as an adjunct to other therapies (like ACE inhibitors and beta-blockers) to improve heart contraction and exercise tolerance.

  • Pediatric Cardiology: The 62.5 mcg strength is frequently used in pediatric dosing for infants and children with congenital heart defects or heart failure.

Mechanism of Action: The “Inotropic & Chronotropic” Effect

Digoxin works through a very specific biochemical pathway in the cardiac myocytes:

Inhibition of the Na+/K+-ATPase Pump: It binds to and inhibits this pump on the cell membrane. This leads to an increase in intracellular sodium ($Na^+$).

Positive Inotropic Effect: The rise in sodium leads to an increase in intracellular calcium ($Ca^{2+}$) via the sodium-calcium exchanger. More calcium means the heart muscle fibers can contract more forcefully (strengthening the heartbeat).

Negative Chronotropic Effect: Digoxin increases vagal (parasympathetic) tone. This slows the heart rate and slows conduction through the Atrioventricular (AV) node, which is crucial for managing rapid heart rhythms like AFib.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Digoxin is a “Narrow Therapeutic Index” (NTI) drug, meaning the difference between a therapeutic dose and a toxic dose is very small.

  • Micro-Dose Precision: Since 62.5 mcg is an extremely minute amount of API, as a WHO-GMP manufacturer, we utilize validated trituration and geometric dilution to ensure absolute content uniformity. A 10% deviation in this product can have life-threatening consequences for the patient.

  • API Sourcing & Stability: Digoxin API must be extremely pure. We monitor for related substances and ensure the product is protected from light and moisture using Alu-Alu blister packaging, ensuring a 36-month shelf life for export to Zone IVb regions.

  • Niche Market Supply: While high-volume items like Paracetamol dominate, Digoxin 62.5 mcg is a vital niche product for specialized B2B distributors and cardiovascular hospitals.

  • Regulatory Compliance: Our Mumbai facility provides full CTD/eCTD Dossiers and bioequivalence studies (which are mandatory for NTI drugs in many countries) to support international registration.

 

Add to cart